Malik Spady, MD
Rheumatology · Covington, LANPI 1649259789
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $105,675 of the $159,818 with a category attached, or 66.1%. 23 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 41.4% of the total. Reporting peaked in 2019 at $38,890 and has fallen 81.5% since, to $7,181 in 2025. Among rheumatology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 839 payments — averaging $190.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$66K
- Mallinckrodt Enterprises LLC$27K
- Johnson & Johnson$26K
- Novartis$20K
- Amgen$7K
- Janssen Scientific Affairs, LLC$6K
- plus $8K from 17 others
What the payments were for
- Consulting fees$16,07910%
- Speaking & faculty fees$105,67566%
- Travel & lodging$21,28113%
- Food & beverage$16,70010%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 106 | $66,110 |
| Mallinckrodt Enterprises LLC | 48 | $27,279 |
| Johnson & Johnson | 62 | $25,638 |
| Novartis | 73 | $19,806 |
| Amgen(2 entities) | 101 | $7,236 |
| Janssen Scientific Affairs, LLC | 8 | $5,973 |
| AbbVie | 163 | $2,551 |
| UCB, Inc. | 66 | $1,100 |
| Pfizer | 72 | $1,044 |
| GSK | 30 | $803 |
| Lilly USA, LLC | 26 | $536 |
| ANI Pharmaceuticals, Inc. | 26 | $494 |
| Aurinia Pharma U.S., Inc. | 18 | $445 |
| E.r. Squibb & Sons, L.L.C. | 13 | $241 |
| Regeneron Healthcare Solutions, Inc. | 10 | $233 |
| Sandoz | 4 | $91 |
| AstraZeneca(2 entities) | 4 | $77 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $41 |
| Radius Health, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$159,818 in reported general payments places this provider in the 95th percentile of 88 rheumatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 63 | $1,260,935 |
| ActharCorticotropin | 22 | $1,056,610 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 117 | $908,993 |
| RinvoqUpadacitinib | 113 | $716,102 |
| MounjaroTirzepatide | 552 | $607,583 |
| Humira(Cf) PenAdalimumab | 61 | $435,861 |
| Enbrel SureclickEtanercept | 59 | $433,482 |
| OtezlaApremilast | 85 | $415,705 |
| OzempicSemaglutide | 333 | $348,872 |
| Taltz AutoinjectorIxekizumab | 44 | $282,473 |
| Cosentyx Sensoready PenSecukinumab | 26 | $270,314 |
| TremfyaGuselkumab | 20 | $269,809 |
| Orencia ClickjectAbatacept | 42 | $239,365 |
| Cosentyx Unoready PenSecukinumab | 30 | $229,652 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 15 | $206,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $66,110 | $1,056,61022 claims |
| AbbVieRinvoq, Linzess, Vraylar, Creon | $2,551 | $856,744317 claims |
| Lilly USA, LLCMounjaro, Forteo, Olumiant, Trulicity | $536 | $727,386602 claims |
| AmgenOtezla, Prolia | $7,236 | $473,959120 claims |
| Johnson & JohnsonTremfya, Simponi | $25,638 | $454,72551 claims |
| GSKBenlysta, Trelegy Ellipta | $803 | $196,24262 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Trintellix | $18 | $119,29447 claims |
| PfizerLitfulo, Nurtec Odt | $1,044 | $69,38936 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,100 | $64,51212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 88 rheumatology providers in Louisiana.
Other rheumatology in Covington
- Jeanine MartinCovington$7K
- Therese Posas-MendozaCovington$6K
- Aaron BroadwellShreveport$1.6M
- Ladislas LazaroLafayette$265K
- Jerry PoundsMetairie$252K
- Carl GauthierHammond$219K
- Sean ShannonBaton Rouge$157K
- Stephen LindseyBaton Rouge$130K
- Agnes SolonAlexandria$123K
- Randall BeylBaton Rouge$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.